Trial Profile

A Phase I Clinical Study of the Safety, Tolerability and Efficacy of BRY812 for Injection in Patients With Advanced Malignancies

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 25 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BRY 812 (Primary)
Indications Advanced breast cancer; Solid tumours
Focus Adverse reactions; First in man
Sponsors BioRay Pharmaceutical

Most Recent Events

07 Nov 2023 Status changed to recruiting, according to a BioRay Pharmaceutical media release.
07 Nov 2023 According to a BioRay Pharmaceutical media release, announced that the first patient has been dosed in the Phase I Clinical trial of BRY812. The leading institution of this clinical trial is Sun Yat-sen Memorial Hospital of Sun Yat-sen University and the principal investigators are academician Song Erwei and Professor Yao Herui.
07 Sep 2023 Status changed from planning to not yet recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com